Heron Therapeutics Sees FY24 Revenue $138M-$158M
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics has reaffirmed its financial guidance for FY24, projecting net product revenues between $138M-$158M, adjusted operating expenses between $108M-$116M, and adjusted EBITDA ranging from a loss of $22M to a gain of $3M, excluding stock-based compensation and depreciation and amortization.
March 12, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Heron Therapeutics projects FY24 net product revenues of $138M-$158M, adjusted operating expenses of $108M-$116M, and adjusted EBITDA of $(22M)-$3M.
The reaffirmation of financial guidance by Heron Therapeutics, especially with a potential positive adjusted EBITDA, is likely to instill confidence in investors about the company's financial health and operational efficiency. This positive outlook could lead to a short-term increase in the stock price as it reflects stability and potential growth.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100